Background
Methods
Data sources
Study design
Study cohorts
Outcomes
Patient baseline characteristics
Secondary analyses
Statistical analyses
Results
Variables | 2002–2006 | 2007–2011 | ||||
---|---|---|---|---|---|---|
Anti-TNF (557) | DMARDs (1144) | Non-users (656) | Anti-TNF (690) | DMARDs (1651) | Non-users (532) | |
Demographics | ||||||
Age (mean (±SD)) years | 63.0(11.5) | 64.2 (10.8) | 65.1 (10.6) | 65.2 (10.5) | 66.2 (9.7) | 68.4 (9.3) |
Sex (female N (%)) | 426 (76.5) | 921 (80.5) | 562 (85.7) | 517 (74.9) | 1281 (77.6) | 426 (80.1) |
Residence (urban N (%)) | 428 (76.8) | 899 (78.6) | 526 (80.2) | 531 (77.0) | 1316 (79.7) | 425 (79.9) |
Higher incomea | 344 (61.8) | 691 (60.4) | 379 (57.8) | 417 (60.4) | 980 (59.4) | 339 (63.7) |
Socioeconomic status N (%) | ||||||
Social quintile 0 | 58 (10.4) | 90 (7.9) | 48 (7.3) | 49 (7.1) | 100 (6.1) | 25 (4.7) |
Social quintile 1 | 106 (19.0) | 211 (18.4) | 88 (13.4) | 113 (16.4) | 285 (17.3) | 74 (13.9) |
Social quintile 2–3 | 192 (34.5) | 392 (34.3) | 238 (36.3) | 251 (36.5) | 618 (37.4) | 218 (41.0) |
Social quintile 4–5 | 201 (36.1) | 451 (39.4) | 282 (43.0) | 276 (40.0) | 648 (39.2) | 215 (40.4) |
Use of health services in prior year N (%) | ||||||
Visit to rheumatologist | 490 (88.0) | 946 (82.7) | 480 (73.2) | 608 (88.1) | 1365 (82.7) | 338 (63.5) |
Comorbidity in prior year N (%) | ||||||
Hematologic disorders | 75 (13.5) | 112 (9.8) | 69 (10.5) | 72 (10.4) | 182 (11.0) | 69 (13.0) |
Heart failure | 16 (2.9) | 29 (2.5) | 9 (1.4) | 19 (2.8) | 38 (2.3) | 23 (4.3) |
Cerebrovascular disease | 21 (3.8) | 23 (2.0) | 19 (2.9) | 10 (1.4) | 39 (2.4) | 22 (4.1) |
Atrial fibrillation | 14 (2.5) | 24 (2.1) | 13 (2.0) | 23 (3.3) | 54 (3.3) | 18 (3.4) |
Ischemic heart disease | 79 (14.2) | 138 (12.1) | 76 (11.6) | 65 (9.4) | 186 (11.3) | 56 (10.5) |
Peptic ulcer disease | 7 (1.3) | 10 (0.9) | 5 (0.8) | 1 (0.1) | 9 (0.5) | 3 (0.6) |
Cancer | 39 (7.0) | 102 (8.9) | 51 (7.8) | 69 (10.0) | 172 (10.4) | 64 (12.0) |
Medication use in prior year N (%) | ||||||
NSAIDs | 430 (77.2) | 843 (73.7) | 452 (68.9) | 435 (63.0) | 980 (59.4) | 248 (46.6) |
Serotonin reuptake inhibitors | 57 (10.2) | 107 (9.4) | 62 (9.5) | 71 (10.3) | 164 (9.9) | 532 (9.6) |
Gastroprotective agents | 322 (57.8) | 664 (58.0) | 345 (52.6) | 463 (67.1) | 970 (58.8) | 328 (61.7) |
Antidiabetics | 63 (11.3) | 115 (10.1) | 51 (7.8) | 81 (11.7) | 170 (10.3) | 77 (14.5) |
Corticosteroid | 414 (74.3) | 757 (66.2) | 400 (61.0) | 500 (72.5) | 928 (56.2) | 306 (57.5) |
Anticoagulants | 27 (4.8) | 49 (4.3) | 31 (4.7) | 32 (4.6) | 106 (6.4) | 34 (6.4) |
Antihypertensives | 294 (52.8) | 587 (51.3) | 305 (46.5) | 414 (60.0) | 944 (57.2) | 335 (63.0) |
Patient baseline characteristics
Variables | 2002–2006 | 2007–2011 | ||
---|---|---|---|---|
OR (95 % CI) | OR (95 % CI) | |||
Anti-TNF vs Non-users | DMARDs vs Non-users | Anti-TNF vs Non-users | DMARDs vs Non-users | |
Demographics | ||||
Residence (rural vs urbain) | 1.21 (0.88, 1.66) | 1.05 (0.81, 1.38) | 1.43 (1.05, 1.96) | 1.15 (0.87, 1.51) |
Higher income | 1.14 (0.90, 1.46) | 1.02 (0.83, 1.26) | 0.76 (0.59, 0.98) | 0.70 (0.56, 0.87) |
Socioeconomic status | ||||
Social quintile 0 | 1.02 (0.62, 1.68) | 0.75 (0.48, 1.17) | 1.33 (0.73, 2.41) | 1.00 (0.59, 1.71) |
Social quintile 2–3 versus 1 | 0.69 (0.48, 0.98) | 0.69 (0.51, 0.93) | 0.71 (0.49, 1.01) | 0.72 (0.53, 0.98) |
Social quintile 4–5 versus 1 | 0.61 (0.43, 0.88) | 0.66 (0.49, 0.90) | 0.82 (0.57, 1.18) | 0.74 (0.54, 1.01) |
Use of health services in prior year | ||||
Visit to rheumatologist | 2.73 (1.97, 3.79) | 1.74 (1.36, 2.22) | 4.41 (3.27, 5.95) | 2.86 (2.29, 3.60) |
Comorbidity in prior year | ||||
Hematologic disorders | 1.32 (0.90, 1.94) | 0.92 (0.66, 1.28) | 0.88 (0.60, 1.30) | 0.96 (0.69, 1.32) |
Heart failure | 1.97 (0.84, 4.61) | 1.95 (0.89, 4.29) | 0.82 (0.41, 1.63) | 0.52 (0.28, 0.94) |
Cerebrovascular disease | 1.43 (0.74, 2.75) | 0.75 (0.39, 1.42) | 0.38 (0.16, 0.86) | 0.63 (0.35, 1.14) |
Ischemic heart disease | 1.06 (0.72, 1.55) | 0.90 (0.64, 1.26) | 0.97 (0.63, 1.50) | 1.33 (0.93, 1.91) |
Cancer | 0.86 (0.55, 1.35) | 1.17 (0.81, 1.69) | 0.82 (0.56, 1.20) | 0.88 (0.64, 1.22) |
Medication use in prior year | ||||
NSAIDs | 1.59 (1.21, 2.09) | 1.26 (1.02, 1.58) | 1.87 (1.46, 2.40) | 1.66 (1.35, 2.05) |
Serotonin reuptake inhibitors | 0.93 (0.62, 1.39) | 0.90 (0.65, 1.26) | 1.08 (0.72, 1.63) | 1.12 (0.79, 1.60) |
Gastroprotective agents | 1.04 (0.81, 1.33) | 1.18 (0.95, 1.45) | 1.09 (0.84, 1.42) | 0.85 (0.68, 1.06) |
Antidiabetics | 1.39 (0.93, 2.08) | 1.28 (0.89, 1.83) | 0.76 (0.52, 1.09) | 0.71 (0.53, 0.97) |
Corticosteroid | 1.87 (1.44, 2.43) | 1.22 (0.99, 1.50) | 1.92 (1.49, 2.47) | 0.96 (0.78, 1.18) |
Anticoagulants | 0.90 (0.50, 1.62) | 0.84 (0.52, 1.37) | 0.98 (0.56, 1.71) | 1.39 (0.89, 2.19) |
Antihypertensives | 1.21 (0.94, 1.57) | 1.20 (0.97, 1.48) | 0.93 (0.72, 1.21) | 0.85 (0.68, 1.06) |
Hospitalizations for MSD-related events
Exposure duration (days) | Hospitalization for musculoskeletal conditions | |||
---|---|---|---|---|
Total | Median (interquartile range) | Number (unadjusted rate per 100 patient-yrs) | Hazard ratio (95 % CI) | |
2002–2006 | ||||
Anti-TNF | 174 128 | 365.0 (79.0) | 39 (8.18) | 0.95 (0.60, 1.50) |
DMARDs | 358 954 | 365.0 (74.0) | 63 (6.41) | 0.69 (0.46, 1.02) |
Non-user | 184 986 | 349.0 (173.0) | 53 (10.46) | 1.00 (Reference) |
2007–2011 | ||||
Anti-TNF | 213 189 | 365.0 (102.0) | 40 (6.85) | 0.65 (0.37, 1.14) |
DMARDs | 527 820 | 635.0 (54.0) | 70 (4.84) | 0.40 (0.24, 0.66) |
Non-user | 148 381 | 349.5 (181.0) | 35 (8.61) | 1.00 (Reference) |
Demographics | 2002–2006 | 2007–2011 |
---|---|---|
Use of health services in prior year | ||
Visit to Rheumatologist | - | 0.51 (0.30, 0.86) |
Comorbidity in prior year | ||
Ischemic heart disease | 2.34 (1.32, 4.13) | 2.69 (1.38, 5.22) |
Medication use in prior year | ||
Antihypertensives | 0.71 (0.47, 1.08) | - |
Secondary analyses
Exposure duration (days) | Number (Unadjusted rate per 100 patient-yrs) | Hazard ratio (95 % CI) | ||
---|---|---|---|---|
Total | Median (Quartile range) | |||
1998–2001 | ||||
DMARDs | 1,243,393 | 365.0 (12.0) | 229 (6.72) | 1.16 (0.95, 1.41) |
Non-users | 1,998,164 | 317.0 (193.0) | 362 (6.61) | 1.00 (Reference) |
2002–2006 | ||||
DMARDs | 1,949,824 | 365.0 (0.0) | 289 (5.41) | 0.86 (0.73, 1.01) |
Non-users | 3,270,739 | 365.0 (169.0) | 614 (6.85) | 1.00 (Reference) |
2007–2011 | ||||
DMARDs | 2,785,950 | 365.0 (0.0) | 344 (4.51) | 0.71 (0.60, 0.84) |
Non-users | 3,970,012 | 296.0 (224.0) | 797 (7.33) | 1.00 (Reference) |